- Option Care Health reported a fourth-quarter net revenue of $1.35 billion, which is a 20% increase compared to the previous year and exceeded the estimate of $1.29 billion.
- Adjusted EBITDA for the quarter was $121.6 million, marking an 8.9% year-over-year increase, surpassing the estimated $118.4 million.
- The company achieved a gross profit of $268.4 million, up by 8.6% from the previous year, and higher than the expected $260.7 million.
- Cash and cash equivalents stood at $412.6 million, a 20% rise year-over-year, although it fell short of the estimated $484.7 million.
- Earnings per share (EPS) were reported at 35 cents, compared to 32 cents in the previous year.
- Analyst recommendations for Option Care Health include 8 buy ratings and 2 hold ratings, with no sell ratings.
Option Care Health on Smartkarma
Analysts at Baptista Research on Smartkarma have provided bullish coverage on Option Care Health, a healthcare company making significant strides in revenue growth and gross profit improvement. In their report titled “Option Care Health: Expansion into Acute Care and Specialty Infusion & Other Major Drivers,” the analysts highlighted the company’s encouraging third-quarter results for 2024. Option Care Health achieved double-digit top-line growth driven by organic growth initiatives, pointing towards a positive outlook for the company’s performance.
Furthermore, Baptista Research analysts published another optimistic report titled “Option Care Health Inc.: How Are The Market & Socio-Demographic Trends Impacting Their Future Revenues? – Major Drivers.” This report detailed Option Care Health‘s solid performance in the second quarter of 2024 despite supply chain disruptions and a cyberattack. The company reported a substantial revenue increase of 14.8% year-over-year, with particular strength noted in newer limited distribution and rare orphan therapies within the chronic portfolio. The analysts’ bullish sentiment underscores the positive trajectory of Option Care Health in navigating market trends and delivering strong financial results.
A look at Option Care Health Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Option Care Health, Inc. is positioned for steady growth and resilience in the long term. According to Smartkarma Smart Scores, the company receives high marks for Growth and Momentum, indicating strong potential for expansion and positive market performance. Combined with decent scores in Value and Resilience, Option Care Health appears well-rounded in its outlook. While the company’s Dividend score is lower, its focus on infusion and home care management solutions for various medical conditions positions it as a key player in the healthcare industry.
With a robust emphasis on providing condition-specific clinical management programs, Option Care Health caters to patients with diverse healthcare needs in the United States. The company’s strategic approach towards offering solutions for a range of conditions, from infectious diseases to heart failures, underscores its commitment to patient care and innovation. Overall, Option Care Health seems to be on a positive trajectory, supported by its strong Growth and Momentum scores, setting the stage for sustained success in the competitive healthcare market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
